`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`
`
`MYLAN PHARMACEUTICALS INC.
`
`Petitioner
`
`v.
`
`YEDA RESEARCH AND DEVELOPMENT CO. LTD.
`
`Patent Owner
`
`Case No. IPR2015-00643
`Patent No. 8,232,250
`
`DECLARATION OF ELEANOR M. YOST
`IN RESPONSE TO PETITIONER’S OBJECTIONS
`TO PATENT OWNER’S EVIDENCE
`
`
`
`
`
`
`
`
`
`
`
`
`
`YEDA EXHIBIT NO. 2149
`MYLAN PHARM. v YEDA
`IPR2015-00643
`
`Page 1 of 11
`
`
`
`
`
`I, Eleanor M. Yost, declare, depose and state the following:
`
`1.
`
`I am counsel to Patent Owner Yeda Research & Development
`
`Co. Ltd. in this proceeding.
`
`2.
`
`I am making this declaration in response to Petitioner’s
`
`Objections to Patent Owner’s Exhibits in IPR2015-0643, dated November 30,
`
`2015.
`
`3.
`
`Exhibit 2028 is a true and accurate copy of slides from a
`
`presentation entitled “Forte: Results from a phase III, 1-year, Randomized,
`
`Double-Blind, Parallel-Group, Dose Comparison Study with Glatiramer Acetate in
`
`Relapse-Remitting Multiple Sclerosis” authored by Giancarlo Comi. These slides
`
`were presented at the World Congress on Treatment and Research in Multiple
`
`Sclerosis: 2008 Joint Meeting of the American, European, and Latin America
`
`Committees on Treatment and Research in Multiple Sclerosis (ACTRIMS,
`
`ECTRIMS, LACTRIMS). Petitioner objects to this exhibit as lacking
`
`authentication under Fed. R. Civ. P. 901. Patent Owner has also submitted
`
`additional evidence authenticating this document. See Ex. 2135 (Ziemssen Decl.)
`
`at ¶ 98.
`
`4.
`
`Exhibit 2031 is a true and accurate copy of the article titled,
`
`“Multiple Sclerosis: Transform Your Clinical Trial with PRA.” I, or those working
`
`
`
`YEDA EXHIBIT NO. 2149
`MYLAN PHARM. v YEDA
`IPR2015-00643
`
`Page 2 of 11
`
`
`
`
`
`under my direction, downloaded a copy of this article on or about October 28,
`
`2015 to a Goodwin Procter LLP computer.
`
`5.
`
`To the extent Petitioner objects to Exhibit 2032 as
`
`“incomplete,” the original will be made available for inspection and copying at the
`
`law offices of Goodwin Procter LLP, 901 New York Avenue NW, Washington,
`
`D.C. 20001.
`
`6.
`
`To the extent Petitioner objects to Exhibit 2037 as
`
`“incomplete,” a complete copy of the public file history of U.S. Pat. Appl.
`
`11/651,212 is available for inspection and copying at the law offices of Goodwin
`
`Procter LLP, 901 New York Avenue NW, Washington, D.C. 20001.
`
`7.
`
`Exhibit 2097 is a true and accurate copy of the Avonex®
`
`(Interferon beta-1a) IM injection (2008) prescribing information. I, or those
`
`working under my direction, downloaded a copy of this document on or about
`
`November 14, 2015 to a Goodwin Procter LLP computer.
`
`8.
`
`Exhibit 2098 is a true and accurate copy of the Rebif
`
`Prescribing Information (2009). I, or those working under my direction,
`
`downloaded a copy of this document on or about November 14, 2015 to a
`
`Goodwin Procter LLP computer.
`
`9.
`
`Exhibit 2099 is a true and accurate copy of the Extavia
`
`Highlights of Prescribing Information (2009). I, or those working under my
`
`
`
`2
`
`YEDA EXHIBIT NO. 2149
`MYLAN PHARM. v YEDA
`IPR2015-00643
`
`Page 3 of 11
`
`
`
`
`
`direction, downloaded a copy of this document on or about November 14, 2015 to
`
`a Goodwin Procter LLP computer.
`
`10. Exhibit 2100 is a true and accurate copy of the Curriculum
`
`Vitae of Edward J. Fox M.D., Ph.D., FAAN.
`
`11. Exhibit 2104 is a true and accurate copy of the Curriculum
`
`Vitae of Dr. Henry George Grabowski.
`
`12. Exhibit 2105 is a true and accurate copy of the List of
`
`Testimony of Dr. Henry George Grabowski.
`
`13. Exhibit 2106 is a true and accurate copy of the Documents
`
`Relied Upon by Dr. Henry George Grabowski. To the extent Petitioner objects to
`
`this exhibit as “incomplete,” the original will be made available for inspection and
`
`copying at the law offices of Goodwin Procter LLP, 901 New York Avenue NW,
`
`Washington, D.C. 20001.
`
`14. Exhibit 2107 is a true and accurate copy of Table: Approval
`
`Timeline, Multiple Sclerosis Drugs. To the extent Petitioner objects to this exhibit
`
`as “incomplete,” the original will be made available for inspection and copying at
`
`the law offices of Goodwin Procter LLP, 901 New York Avenue NW, Washington,
`
`D.C. 20001.
`
`15. Exhibit 2108 is a true and accurate copy of Figure: Copaxone®
`
`40 mg/mL Wholesale Dollar Sales (Q1 2014- Q3 2015). To the extent Petitioner
`
`
`
`3
`
`YEDA EXHIBIT NO. 2149
`MYLAN PHARM. v YEDA
`IPR2015-00643
`
`Page 4 of 11
`
`
`
`
`
`objects to this exhibit as “incomplete,” the original will be made available for
`
`inspection and copying at the law offices of Goodwin Procter LLP, 901 New York
`
`Avenue NW, Washington, D.C. 20001.
`
`16. Exhibit 2109 is a true and accurate copy of Figure: Copaxone®
`
`40 mg/mL Extended Units (Q1 2014- Q3 2015). To the extent Petitioner objects to
`
`this exhibit as “incomplete,” the original will be made available for inspection and
`
`copying at the law offices of Goodwin Procter LLP, 901 New York Avenue NW,
`
`Washington, D.C. 20001.
`
`17. Exhibit 2110 is a true and accurate copy of Figure: Copaxone®
`
`40 mg/mL Total Prescriptions (Q1 2014- Q3 2015). To the extent Petitioner
`
`objects to this exhibit as “incomplete,” the original will be made available for
`
`inspection and copying at the law offices of Goodwin Procter LLP, 901 New York
`
`Avenue NW, Washington, D.C. 20001.
`
`18. Exhibit 2111 is a true and accurate copy of Figure: Copaxone®
`
`40 mg/mL New Prescriptions (Q1 2014- Q3 2015). To the extent Petitioner objects
`
`to this exhibit as “incomplete,” the original will be made available for inspection
`
`and copying at the law offices of Goodwin Procter LLP, 901 New York Avenue
`
`NW, Washington, D.C. 20001.
`
`19. Exhibit 2112 is a true and accurate copy of Figure: Multiple
`
`Sclerosis Drugs Share of Wholesale Dollar Sales (Q4 2009- Q3 2015). To the
`
`
`
`4
`
`YEDA EXHIBIT NO. 2149
`MYLAN PHARM. v YEDA
`IPR2015-00643
`
`Page 5 of 11
`
`
`
`
`
`extent Petitioner objects to this exhibit as “incomplete,” the original will be made
`
`available for inspection and copying at the law offices of Goodwin Procter LLP,
`
`901 New York Avenue NW, Washington, D.C. 20001.
`
`20. Exhibit 2113 is a true and accurate copy of Figure: Multiple
`
`Sclerosis Drugs Share of Total Prescriptions (Q4 2009- Q3 2015). To the extent
`
`Petitioner objects to this exhibit as “incomplete,” the original will be made
`
`available for inspection and copying at the law offices of Goodwin Procter LLP,
`
`901 New York Avenue NW, Washington, D.C. 20001.
`
`21. Exhibit 2114 is a true and accurate copy of Figure: Multiple
`
`Sclerosis Drugs Share of New Prescriptions (Q4 2009- Q3 2015). To the extent
`
`Petitioner objects to this exhibit as “incomplete,” the original will be made
`
`available for inspection and copying at the law offices of Goodwin Procter LLP,
`
`901 New York Avenue NW, Washington, D.C. 20001.
`
`22. Exhibit 2115 is a true and accurate copy of Figure: Rationale
`
`for Requesting Copaxone. To the extent Petitioner objects to this exhibit as
`
`“incomplete,” the original will be made available for inspection and copying at the
`
`law offices of Goodwin Procter LLP, 901 New York Avenue NW, Washington,
`
`D.C. 20001.
`
`23. Exhibit 2116 is a true and accurate copy of Figure: Perception
`
`of 3-times-a-week Copaxone 40mg compared to Daily Copaxone 20 mg. To the
`
`
`
`5
`
`YEDA EXHIBIT NO. 2149
`MYLAN PHARM. v YEDA
`IPR2015-00643
`
`Page 6 of 11
`
`
`
`
`
`extent Petitioner objects to this exhibit as “incomplete,” the original will be made
`
`available for inspection and copying at the law offices of Goodwin Procter LLP,
`
`901 New York Avenue NW, Washington, D.C. 20001.
`
`24. Exhibit 2117 is a true and accurate copy of Figure: Rationale
`
`for Discussing 20 mg and 40 mg for First Line Patients. To the extent Petitioner
`
`objects to this exhibit as “incomplete,” the original will be made available for
`
`inspection and copying at the law offices of Goodwin Procter LLP, 901 New York
`
`Avenue NW, Washington, D.C. 20001.
`
`25. Exhibit 2118 is a true and accurate copy of Figure: Perceptions
`
`of Copaxone® 40 mg compared to Daily Generic GA. To the extent Petitioner
`
`objects to this exhibit as “incomplete,” the original will be made available for
`
`inspection and copying at the law offices of Goodwin Procter LLP, 901 New York
`
`Avenue NW, Washington, D.C. 20001.
`
`26. Exhibit 2119 is a true and accurate copy of Figure: Perceptions
`
`of Copaxone® 40 mg vs. 20 mg. To the extent Petitioner objects to this exhibit as
`
`“incomplete,” the original will be made available for inspection and copying at the
`
`law offices of Goodwin Procter LLP, 901 New York Avenue NW, Washington,
`
`D.C. 20001.
`
`27. Exhibit 2120 is a true and accurate copy of Figure: Copaxone®
`
`Total Prescriptions (Q4 2009- Q3 2015). To the extent Petitioner objects to this
`
`
`
`6
`
`YEDA EXHIBIT NO. 2149
`MYLAN PHARM. v YEDA
`IPR2015-00643
`
`Page 7 of 11
`
`
`
`
`
`exhibit as “incomplete,” the original will be made available for inspection and
`
`copying at the law offices of Goodwin Procter LLP, 901 New York Avenue NW,
`
`Washington, D.C. 20001.
`
`28. Exhibit 2121 is a true and accurate copy of Figure: Copaxone®
`
`20 mg/mL, Copaxone® 40 mg/mL, and Glatopa™ Net Prescriptions Flow
`
`(10/26/12- 10/9/15). To the extent Petitioner objects to this exhibit as
`
`“incomplete,” the original will be made available for inspection and copying at the
`
`law offices of Goodwin Procter LLP, 901 New York Avenue NW, Washington,
`
`D.C. 20001.
`
`29. Exhibit 2122 is a true and accurate copy of Table: Total
`
`Promotional Spending to Sales Ratio. To the extent Petitioner objects to this
`
`exhibit as “incomplete,” the original will be made available for inspection and
`
`copying at the law offices of Goodwin Procter LLP, 901 New York Avenue NW,
`
`Washington, D.C. 20001.
`
`30. Exhibit 2129 is a true and accurate copy of the Declaration of
`
`Edward J. Fox M.D., Ph.D.
`
`31. Exhibit 2130 is a true and accurate copy of the Curriculum
`
`Vitae of Robert William Gristwood, Ph.D.
`
`32. Exhibit 2131 is a true and accurate copy of the Curriculum
`
`Vitae of Tjalf Ziemssen.
`
`
`
`7
`
`YEDA EXHIBIT NO. 2149
`MYLAN PHARM. v YEDA
`IPR2015-00643
`
`Page 8 of 11
`
`
`
`
`
`33. Exhibit 2132 is a true and accurate copy of Ziemssen’s MS
`
`Clinical Trials.
`
`34. Exhibit 2133 is a true and accurate copy of the Declaration of
`
`Henry G. Grabowski, Ph.D.
`
`35. Exhibit 2134 is a true and accurate copy of the Declaration of
`
`Robert William Gristwood, Ph.D.
`
`36. Exhibit 2135 is a true and accurate copy of the Declaration of
`
`Tjalf Ziemssen, M.D., Ph.D.
`
`
`
`8
`
`YEDA EXHIBIT NO. 2149
`MYLAN PHARM. v YEDA
`IPR2015-00643
`
`Page 9 of 11
`
`
`
`
`
`I declare that all statements made herein of my own knowledge are true and
`
`that all statements made on information and belief are believed to be true; and
`
`further that these statements and the like so made are punishable by fine or
`
`imprisonment, or both, under Section 1001 of Title 18 of the United States Code.
`
`I declare under penalty of perjury that the foregoing is true and correct.
`
`Executed in Washington, D.C. on December 14, 2015.
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Eleanor M. Yost
`
`
`
`9
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`YEDA EXHIBIT NO. 2149
`MYLAN PHARM. v YEDA
`IPR2015-00643
`
`Page 10 of 11
`
`
`
`CERTIFICATE OF SERVICE
`
`The undersigned certifies service of the foregoing Declaration on December
`
`14, 2015 pursuant to 37 C.F.R. § 42.6(e) on the Petitioner via email as follows:
`
`
`
`Jeffrey W. Guise
`
`jguise@wsgr.com
`
`Brandon M. White
`
`BMWhite@perkinscoie.com
`
`Shannon Bloodworth
`
`Sbloodworth@perkinscoie.com
`
`David Anstaett
`
`DAnstaett@perkinscoie.com
`
`Richard Torczon
`
`rtorczon@wsgr.com
`
`
`
`/Eleanor Yost/
`
`Eleanor M. Yost
`
`
`
`
`
`
`
`YEDA EXHIBIT NO. 2149
`MYLAN PHARM. v YEDA
`IPR2015-00643
`
`Page 11 of 11